Müzeyyen Aksoy

Dr. Müzeyyen Aksoy

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2025 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
MAMüzeyyen Aksoy
Müzeyyen Aksoy
EIEnes Emir İlErler
Enes Emir İlErler
SKSait Karakurt
Sait Karakurt
MSMesut Sancar
Mesut Sancar
Polypharmacy, resulting from the medications used in the management of sepsis, along with the pharmacokinetic changes induced by sepsis, can place this patient population at increased risk for drug-related problems (DRPs). Clinical pharmacists contribute to reducing DRPs by providing medication review services, which involve a comprehensive evaluation of a patient’s medications. The aim of this study was to identify and classify DRPs in patients with sepsis and septic shock who were hospitalized in the intensive care unit (ICU), and to evaluate the effect of clinical pharmacist-led medication review on DRPs. The study was a prospective, non-randomized controlled study conducted in the medical ICU of a tertiary education and research hospital in Istanbul, Türkiye, from October 2023 to May 2024. The study design included both observation periods (OP) and intervention periods (IP). During the IP, the clinical pharmacist provided recommendations to prevent or resolve DRPs during daily rounds and conducted DRP-reducing presentations to the clinical team on DRPs frequently observed during the OP. DRPs were classified according to Pharmaceutical Care Network (PCNE) Version 9.1 and their clinical significance in collaboration with the chief of ICU. A total of 60 patients were included in the study. The mean age of all patients was 62.6 ± 17.4 years and 58.3% were male. A total of 354 (5.9/patient) DRPs were detected in all periods. Of these DRPs, 50.1% were classified as “adverse drug event (possibly) occurring”, 30.8% as “effect of drug treatment not optimal”, 5.6% as “unnecessary drug treatment”, 2.8% as “untreated symptoms or indications”, and 10.7% as “unclear problem/complaint”. In the IP, the number of all DRPs decreased by 63.3% (p < 0.001) and the frequency of clinically significant major DRPs decreased by 84.8% (p = 0.008). During the IP, recommendations were made for 72 of the 95 DRPs identified and 70 of these recommendations (97.2%) were accepted by physicians. A high incidence of DRP was detected in patients with sepsis hospitalized in the ICU. The majority of clinical pharmacist recommendations were accepted by the ICU team. The number of DRPs decreased significantly during the IP.

12 February 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
YAYunus Emre emre Ayhan
Yunus Emre emre Ayhan
MAMüzeyyen Aksoy
Müzeyyen Aksoy
YAYahya Abdulrahman
Yahya Abdulrahman
ZEZeynep Safiye Şahin Eröksüz
Zeynep Safiye Şahin Eröksüz
DVDuygu Vezir
Duygu Vezir
MSMesut Sancar
Mesut Sancar
Background: Pulmonary embolism (PE) poses significant morbidity and mortality risks, necessitating tailored anticoagulant therapy. Limited studies investigate the drug-related problems (DRPs) in PE. This study aims to evaluate the impact of clinical pharmacist (CP) interventions on drug-related problems (DRPs) and clinical outcomes in outpatients with PE. By addressing DRPs in this specific population, the study seeks to assess the role of CP-led interventions in enhancing patient safety and optimizing treatment outcomes. Methods: A randomized controlled trial was conducted on PE patients at a pulmonology outpatient clinic over the period of 15 January 2022 to January 2023. In this trial, the intervention group (IG) benefited from CP recommendations targeting DRPs, while the control group (CG) was observed without any additional interventions. Follow-ups were conducted at 90 and 180 days post-discharge. The study focused on DRPs, CP interventions, and patient outcomes. Data were systematically recorded and analyzed, adhering to ethical standards and employing the PCNE v9.1 classification system. Results: The study followed 50 PE patients, with 26 in the IG and 24 in the CG. DRPs, mostly in drug and dose selection, affected 84% of participants (3.34 DRPs/patient). In the IG, the CP made 76 recommendations (91.5%) for 83 DRPs at the prescribing physician level. Majority of these recommendations (94.7%) were accepted. At the 90-day follow-up, bleeding occurred in 16.6% of the CG, with none in the IG (odds ratio [OR] = 2.3, 95% confidence interval [CI]: 1.654–3.198, p = 0.046). As indicated by Cramér’s V (0.307), the effect size demonstrated a moderate association between the intervention and the absence of bleeding events in the IG. At the 180-day follow-up, bleeding was 33.3% in the CG and 16.6% in the IG (p = 0.443). Conclusions: PE patients experience common and frequent DRPs, especially in anticoagulation therapy. CP recommendations are widely accepted but need to be better implemented. No bleeding events were observed in the IG where a CP was involved at 90 days, unlike the CG. Including a CP in the PE treatment team seems to influence outcomes positively.

13 October 2025 in Trends in Pharmacy
Verified
Journal Article
Open access
PDF file
MAMüzeyyen Aksoy
Müzeyyen Aksoy
Pain, anxiety, agitation, and delirium are common in intensive care unit (ICU) patients, particularly in those undergoing invasive procedures such as intubation and mechanical ventilation. Initiating sedation without first evaluating and treating pain is not rational, as it may mask underlying discomfort and delay appropriate management. Deep sedation, when applied without careful assessment, is associated with prolonged mechanical ventilation, extended ICU stay, and increased mortality; therefore, it should be reserved only for specific clinical indications, as emphasized in the Society of Critical Care Medicine Pain, Agitation, and Delirium Guidelines. Pain, a major trigger of agitation, requires systematic assessment and early, multimodal analgesia—combining opioid and non-opioid strategies—to reduce adverse outcomes, minimize opioid exposure, and support faster recovery. Agitation may otherwise result in complications including self-extubation, catheter dislodgement, and ventilator asynchrony, necessitating judicious use of sedatives and analgesics in ICU care. Delirium, characterized by disturbances in attention, consciousness, and cognition, is strongly linked to increased mortality and long-term cognitive impairment. Guidelines recommend routine delirium screening, environmental modifications, structured sleep protocols, and early mobilization, along with careful pharmacological strategies. Antipsychotics are not advised for prophylaxis, while dexmedetomidine may be considered in selected ventilated patients. Optimal triad management requires individualized drug selection, validated assessment tools, and minimal benzodiazepine use except in cases such as withdrawal. In addition to guideline-based strategies, growing evidence highlights the role of clinical pharmacists, whose interventions in drug selection, dose titration, monitoring, and interprofessional education have been shown to reduce sedative and opioid exposure, shorten mechanical ventilation and ICU stay, and improve cost-effectiveness. This review synthesizes guideline-based recommendations, recent evidence, and the expanding contributions of clinical pharmacists to provide practical, evidence-based strategies for clinicians managing pain, sedation, and delirium in the ICU.

5 January 2026 in Ankara Universitesi Eczacilik Fakultesi Dergisi
Verified
Journal Article
Closed access
DÜDuygu Ünder
Duygu Ünder
BÖBetül Özgan
Betül Özgan
MAMüzeyyen Aksoy
Müzeyyen Aksoy
EIEnes Emir İlErler
Enes Emir İlErler
ÖÖÖmer Faruk Özkanlı
Ömer Faruk Özkanlı
STSongul Tezcan
Songul Tezcan
Objective: The clinical pharmacy specialization program (CPSEP), initiated in 2018, aims to train expert pharmacists for clinical pharmacy services in hospitals. No study has yet evaluated medication therapy recommendations within the first "clinical pharmacy consultation system (CPCS)" integrated into Türkiye’s hospital framework. This study aims to assess the clinical pharmacy services delivered through the CPCS. Material and Method: This study was conducted on a tertiary-level hospital in Istanbul between February 2024-January 2025. The first 11 months of CPCS integration were evaluated. Result and Discussion: Sixty-nine patients were consulted, mostly adults (59.4%), primarily in hospital wards (65.2%) and intensive care units (26.1%). Common diagnoses included acute kidney injury (34.8%), infections (29.0%), and hematological malignancies (18.8%). Patients had a median of 9 medications (IQR, 8–15) and 2 comorbidities (IQR, 1–3). Common consultation reasons were adverse drug reactions (39.1%), potential drug interactions (27.5%), medication errors (14.5%), and inappropriate drug selection (5.8%). Eighty recommendations were provided, mostly regarding drug/laboratory monitoring (44.9%), dose adjustments (15.9%), and drug initiation/substitution (15.9%). Most consultations (84.1%) involved a single recommendation. These findings indicate that CPCS is actively used in drug therapy management within the national healthcare system. Although around five similar systems have been integrated in Turkish hospitals since 2023, this study presents the first published results of CPCS.

4 August 2026 in Scientific Reports
Verified
Journal Article
Open access
PDF file
MAMüzeyyen Aksoy
Müzeyyen Aksoy
EIEnes Emir Ilerler
Enes Emir Ilerler
EYErdem Yalcinkaya
Erdem Yalcinkaya
UKUmut Sabri Kasapoglu
Umut Sabri Kasapoglu
HAHuseyin Arikan
Huseyin Arikan
MSMesut Sancar
Mesut Sancar
Sepsis and septic shock are associated with profound pathophysiological changes that alter drug pharmacokinetics, complicating optimal medication dosing in critically ill patients. Inadequate understanding of these alterations may result in inappropriate drug exposure, potentially leading to treatment failure or toxicity. This study aimed to assess healthcare professionals’ knowledge, attitudes, and behaviors regarding pharmacokinetic-guided drug dosing in sepsis and septic shock. A cross-sectional survey study was conducted among physicians and clinical pharmacists in Türkiye between September and December 2025. A structured questionnaire was developed using a modified Delphi process and assessed knowledge, attitudes, behaviors, and clinical application through a dosing scenario. A total of 203 healthcare professionals participated. The mean knowledge score was 3.67 ± 1.70 out of 7, with only 31.5% demonstrating high knowledge levels. Notable gaps were identified in areas such as anticoagulant dosing and pharmacokinetic changes during continuous renal replacement therapy. Despite these gaps, participants reported positive attitudes toward individualized dosing (mean score: 4.25 ± 0.30) and generally favorable practices (mean score: 4.00 ± 0.64). Clinical pharmacists demonstrated significantly higher knowledge scores than physicians (p < 0.001) and greater accuracy in the clinical scenario (94.1% vs. 72.8%, p = 0.008). Substantial knowledge gaps exist among healthcare professionals regarding pharmacokinetic-guided drug dosing in sepsis. The identified knowledge gaps may increase the risk of inappropriate dosing decisions, although actual prescribing behavior, drug exposure, and patient outcomes were not evaluated. Targeted educational interventions and strengthened multidisciplinary collaboration are essential to support safer and more effective medication use in the intensive care setting.

19 September 2026 in Ankara Universitesi Eczacilik Fakultesi Dergisi
Verified
Journal Article
Closed access
ZBZüleyha Bakay
Züleyha Bakay
MAMüzeyyen Aksoy
Müzeyyen Aksoy
ÖÖÖmer Faruk Özkanlı
Ömer Faruk Özkanlı
MSMesut Sancar
Mesut Sancar
Objective: Obesity, with its growing global prevalence, is recognized as a significant risk factor for chronic diseases such as diabetes, dyslipidemia, and certain cancers. It also increases the risk of infections like bacteremia, surgical site infections, and soft tissue infections, thereby raising morbidity and mortality. In obese individuals, both adipose and muscle mass increase, but adipose tissue expands disproportionately, altering the volume of distribution (Vd) of drugs. This necessitates using specific body weight descriptors—ideal, total, adjusted, or lean body weight—for accurate dosing. No single descriptor suits all drugs; dosing should be drug-specific. For example, using ideal body weight for lipophilic drugs with a large Vd may lead to subtherapeutic levels, while using total body weight for hydrophilic drugs with a small Vd may cause toxicity. Obesity also alters hepatic and renal functions, impacting drug metabolism and clearance. These changes mainly affect drugs with high hydrophilicity or lipophilicity, notably antimicrobials and sedative-analgesics.Result and Discussion: This review discusses current evidence on pharmacokinetic alterations in obese patients and provides guidance on selecting appropriate weight descriptors to ensure optimal dosing in this population.